Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple MyelomaDecember 12, 2018
XPO1 inhibition restores the ability of intranuclear tumor suppressor genes to disrupt oncoproteins; it is emerging as a promising new investigational strategy in MM.
New research confirms that gut microbiome dysbiosis is present in survivors of childhood acute lymphoblastic leukemia.
Researchers identified a single heterozygous nucleotide variant that confers resistance to venetoclax, and it's a mutation that may be detected years before clinical relapse occurs.
Investigators identify a novel role of the genes located on chr17p13 in the induction of apoptosis in multiple myeloma.
Continuous therapy appears to be the preferred treatment modality in newly diagnosed patients with multiple myeloma (MM).
EUTOS long-term survival score better predicted prognosis for those with chronic myeloid leukemia who had been treated with TKIs—especially among elderly patients.
The findings may support the triplet regimen as a new standard of care for these patients, according to Dr Facon.
Three-year outcomes reveal a new standard of care in patients with CLL who are younger than 70.
Although results indicated rivaroxaban decreased the risk of VTE and VTE-related death in patients with cancer, the benefit was not maintained at study conclusion.
Clonal hematopoiesis of indeterminate potential is associated with shorter overall and event-free survival after autologous transplant in lymphoma.
A readout of results from a phase 1 trial featuring MCARH171 demonstrates the potential of the human-derived BCMA-targeted CAR-T for R/R MM.
CAR-T cells targeting CD19 and CD20 were successfully and reproducibly produced at the point-of-care within 14 days.
Loss of intestinal bacterial diversity in patients undergoing AHCT may be comparable to reductions experienced by patients undergoing alloHCT.
BCMA expression did not correlate with clinical response.
Patients saw a deepening of responses over time.
AMG 420 is an anti-B cell maturation antigen bispecific T cell engager antibody construct.
Early results of phase 1, dose-escalation trial demonstrate efficacy and safety of P-BCMA-101 CAR-T cell therapy in patients with R/R MM.
The investigational antibody construct exploits the power of native effector T cells, supporting antitumor activity shortly after administration.
Restricting MM cancer cells from making contact with the bone marrow microenvironment may be achieved through the delivery of inhibitors through nanoparticles.
The construct from Allogene has been engineered to avoid the serious immune-related complications linked to allogeneic transplantation.
Bendamustine-rituximab combination increased risk for day 1 stem cell mobilization failure
Mohamad Mohty, MD, PhD, discusses the latest research at ASH 2018.
Nancy Simonian, MD, discusses the results at ASH 2018.
Habte Yimer, MD, discusses his findings at the ASH 2018 meeting.
Genetically defined mouse models of AEL could help researchers find novel treatment approaches.
Nizar Bahlis, MD, discusses his findings at the ASH 2018 meeting.
John Burke, MD, discusses the latest research at ASH 2018.
Although PFS with ibrutinib-containing regimens was favorable compared with bendamustine rituximab, overall survival was not different across the study arms.
Charles G. Mullighan, MBBS (Hons), MSc, MD, discusses the latest research out of St Jude at ASH 2018.
Luspatercept Reduced RBC Transfusion Dependence in Lower-Risk Patients With Myelodysplastic SyndromesDecember 02, 2018
Findings from the MEDALIST trial revealed a significant reduction in transfusion burden for patients being treated with luspatercept compared with placebo
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?